AbbVie’s $744 Million Gut Punch Shakes 2026 Outlook For Chicago Investors
AbbVie said it will take a $744M pre‑tax charge for acquired IPR&D and milestone costs, trimming its 2026 adjusted EPS guidance to $13.96–$14.16. The hit reflects deal‑driven pipeline spending even as the company presses local investments.












